Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14196261 | 1.00 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL22215286 | 1.00 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL4841218 | 0.98 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL12362618 | 0.87 | NOS2 (0.38) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL24242503 | 0.87 | NOS2 (0.38) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL5646119 | 0.86 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL20362240 | 0.85 | NOS2 (0.37) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL28747733 | 0.84 | SLC6A2 (0.35) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL13503192 | 0.80 | — | — | |
| SCHEMBL13503178 | 0.78 | NOS3 (0.35) | SLC6A4SLC6A2SLC6A3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023249871-A1 | SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| WO-2023066204-A1 | SIK INHIBITOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2021215544-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| CN-106573907-B | Quinoline derivatives and their use for neurodegenerative diseases | 默克专利有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-04-25 | — | — | US | disclosed |
| EP-3152192-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | Merck Patent GmbH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-7235580-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | SLC6A4 161/4885SLC6A2 99/4885SLC6A3 97/4885 |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | KRAS, NRAS, HRAS | SLC6A4 4720/4885SLC6A2 4755/4885SLC6A3 4622/4885 |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | SLC6A4 3967/4885SLC6A2 4562/4885SLC6A3 3792/4885 |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK2 | SLC6A4 3967/4885SLC6A2 4562/4885SLC6A3 3792/4885 |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | SLC6A4 161/4885SLC6A2 99/4885SLC6A3 97/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SLC6A4 1093/4885SLC6A2 1393/4885SLC6A3 1466/4885 |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK2, DYRK3 | SLC6A4 3515/4885SLC6A2 4314/4885SLC6A3 3194/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | SLC6A4 4341/4885SLC6A2 3189/4885SLC6A3 4331/4885 |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | SLC6A4 3629/4885SLC6A2 4458/4885SLC6A3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.